Nevro Corp (NVRO)
5.29
+0.09
(+1.73%)
USD |
NYSE |
Sep 27, 16:00
5.285
0.00 (0.00%)
After-Hours: 20:00
Nevro SG&A Expense (Annual): 334.70M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 334.70M |
December 31, 2022 | 322.14M |
December 31, 2021 | 309.31M |
December 31, 2020 | 267.15M |
December 31, 2019 | 305.81M |
December 31, 2018 | 266.61M |
Date | Value |
---|---|
December 31, 2017 | 219.71M |
December 31, 2016 | 142.42M |
December 31, 2015 | 82.47M |
December 31, 2014 | 29.78M |
December 31, 2013 | 18.83M |
December 31, 2012 | 14.09M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
267.15M
Minimum
2020
334.70M
Maximum
2023
307.82M
Average
309.31M
Median
2021
SG&A Expense (Annual) Benchmarks
Myomo Inc | 18.78M |
Inspire Medical Systems Inc | 451.96M |
Axonics Inc | 235.32M |
Inari Medical Inc | 361.06M |
Electromed Inc | 34.49M |